This case gives the court an opportunity to rein in the growing use of patents to protect genetically engineered crops and other life forms.

A federal appeals court overturned the prior decision, ruling that Myriad Genetics could indeed hold patents to two genes that help forecast a woman's risk of breast cancer.

Last year the Supreme Court restricted the scope of such business-process patents, but not by enough to satisfy critics.